Cancer Types | Colorectal Cancer - NFCR

Colorectal Cancer

Colorectal Cancer

Colorectal cancer is the third most common cancer diagnosed in both men and women in the U.S. Although the death rate from colorectal cancer has been dropping for the past 30 years, it is still the third leading cause of cancer death for both men and for women in the U.S.

Key Facts

  • There are currently more than one million colorectal cancer survivors in the U.S.
  • The overall lifetime risk of developing colorectal cancer is 1 in 23 for men and 1 in 25 for women.
  • With regular screenings, colorectal cancer can be preventable.
  • The age for colorectal cancer screening is now 45 years instead of 50 years.
  • Several factors may place you at a higher risk for colorectal cancer, including age, personal history of polyps or cancer, inflammatory bowel disorders, type 2 diabetes, family history, genetics and lifestyle choices, such as low physical activity, obesity, smoking, moderate to heavy alcohol use, very low intake of fruits and vegetables, and diets high in red and processed meats.
Source: American Cancer Society’s Cancer Facts & Figures 2021

Signs and Symptoms

A symptom is a change in the body that a person can see and/or feel. A sign is a change that the doctor sees during an examination or on a laboratory test result. If you have any of the symptoms below, it does not mean you have cancer but you should see your doctor or health care professional so that the cause can be found and treated, if needed.

  • A change in bowel habits, such as diarrhea, constipation, or narrowing of the stool, that lasts for more than a few days
  • A feeling that you need to have a bowel movement that’s not relieved by having one
  • Rectal bleeding with bright red blood
  • Blood in the stool, which might make the stool look dark brown or black
  • Cramping or abdominal (belly) pain
  • Weakness and fatigue
  • Unintended weight loss
Source: American Cancer Society 2021
dark blue colorectal cancer ribbon
1000000
or more survivors in the U.S. today
1
in 23 men will be diagnosed
1
in 25 women will be diagnosed

Colorectal Cancer Research

In addition to specific projects listed below, genomics research is helping us attack colorectal cancer – and all types of cancer. NFCR has distinguished itself from other organizations by emphasizing long-term, transformative research and working to move people toward cancer genomics.

NFCR Fellow Dr. Yung-Chi Cheng
Yung-Chi Cheng, Ph.D.

With NFCR funding since 1991, Dr. Yung-Chi Cheng and his team developed YIV-906, a botanical drug that enhances anti-cancer activity in immunotherapy, chemotherapy and radiotherapy. YIV-906 also reduces the unpleasant gastrointestinal side effects of chemotherapy. Patients with colon and rectal cancers were some of the first patients to experience these beneficial properties of YIV-906 in early Phase I clinical trials.

With support from the NFCR AIM-HI Translational Research Initiative, Dr. Cheng has now brought YIV-906 to a global Phase II clinical trial in 2020. YIV-906 is first treating Hepatitis B Virus (HBV)-associated liver cancer patients in combination with sorafenib, a front-line drug that has modest response rates and serious toxicities. If YIV-906 improves patients’ outcomes, it could become one of the first FDA-approved oral herbal medicines for anti-cancer treatment. Its acceptance as an approved drug would facilitate future clinical trials to benefit patients with other types of cancer. Significantly, since YIV-906 affects multiple biological systems, it will usher in a new model for drug discovery to treat patients holistically.

James P. Basilion, Ph.D.
James P. Basilion, Ph.D.

The best chance for a cure for many cancers is complete and successful surgery. Dr. Jim Basilion has developed a “smart” probe that when topically applied to cancer during surgery, lights up only cancer cells and improving the surgeon’s ability to detect tumor margins. Usually, an assessment of margins is done after the surgical procedure and patients return home. The smart probe will fulfill the unmet clinical need to reduce repeat surgeries and remove remaining colon, prostate, breast and lung cancer. Significantly, the ‘smart’ probe may reduce the chance of cancer spreading, increasing the rate of a surgical cure. With support from the NFCR AIM-HI Translational Research Initiative, the probe is being optimized towards a Phase I clinical trial initially for lumpectomies to further enhance cure rates for patients with early stage breast cancer. Success with this trial will facilitate clinical use of this “smart” probe for patients with colon and other cancers.

Daniel Von Hoff, M.D
Daniel Von Hoff, M.D

Dr. Daniel Von Hoff has developed an antibody pipeline to create strategic therapies of ‘monoclonal antibodies’ – proteins that specifically bind and inhibit one substance. The first monoclonal antibodies in development are those that bind to a key molecular ‘target’ found on fibrotic cells that surround many types of cancer. Targets bound with antibody can no longer signal to tumor cells to metastasize from the primary tumor. Dr. Von Hoff has personally been involved in over 200 clinical trials and his team is focusing the first monoclonal antibody therapy for patients with metastatic colorectal cancer who no longer respond to their current medicine. With NFCR funding, promising monoclonal antibodies are in final pre-clinical stages and may soon enter clinical trials to treat colorectal cancer patients who need a new effective treatment to save their lives. The strategic monoclonal antibodies to stop metastasis in pancreatic and lung cancer will be a future application.

Wei Zhang, Ph.D.
Wei Zhang, Ph.D.

Dr. Wei Zhang is a leader of precision oncology, using NFCR support since 2006 to characterize underlying genetic mechanisms responsible for cancer growth and progression. His research addresses the variability in cellular properties, within and across cancer types, which often leads to treatment resistance and poor survival in patients. Dr. Zhang previously identified microRNAs (miRNAs) as biomarkers to improve colorectal cancer prognosis and predict treatment response. Dr. Zhang’s precision oncology approach has the potential to improve outcomes for patients with colorectal cancer.

Xiang-Lei Yang, Ph.D. and Paul Schimmel, Ph.D.
Xiang-Lei Yang, Ph.D. and Paul Schimmel, Ph.D.

Aminoacyl-tRNA synthetases (aaRS) are vital ancient enzymes that make proteins in all living things. Dr. Paul Schimmel and Dr. Xiang-Lei Yang, experts in aaRS research, also study the enzyme’s other unexpected roles. One aaRS, SerRS, inhibits a pro-cancer gene and thwarts cancer’s growth and may play a role in activating the immune system to inhibit tumor progression. Expression of SerRS positively correlates with greater survival in patients with triple negative breast cancer as well as those with rectal, esophageal, kidney, and thyroid cancers as well as gliomas (brain cancer). SerRS may also be a suppressor of metastasis as enzyme levels are significantly decreased in breast tissue during metastasis. This critical research may lead to a novel way to treat cancer, offering hope to patients.

Related Content

Coping With Cancer—It’s Different for Everyone

Everyone’s journey with cancer is different, also unique to them is the way in which they cope with the disease. Taking two late celebrities, Alex Trebek and Chadwick Boseman as an example, we can see the differences in how individuals deal with a cancer diagnosis. Pancreatic cancer may only rank at number nine and ten in terms of most commonly diagnosed cancers amongst men and women (respectively), but most Americans are well aware of the disease ever since Jeopardy host Alex Trebek was diagnosed last year. The deadly disease has a low five-year-survival rate at only 9%. Most Americans are well aware of the disease ever since the late Jeopardy host Alex Trebek was diagnosed in 2019 and sadly passed away in November 2020. Though undoubtedly a trying year for Trebek, his loved ones, and his fans, the game show host publicly battled his cancer with his return to Jeopardy in September 2020. A year-and-a-half after being diagnosed with stage 4 cancer, Trebek became an inspiration for many affected by pancreatic cancer. Despite the side effects, which include fatigue, Trebek returned to the Jeopardy stage to do what he loved most. His passion for living life had his recently published memoir flying off the shelves. Appropriately titled ‘The Answer Is…: Reflections on My Life’, the memoir explores Trebek’s entire life to date – including his childhood through to his life during the COVID-19 pandemic. Though the memoir is not a story specifically about his cancer journey, Trebek used his fame to bring awareness to pancreatic cancer. In partnership with the World Pancreatic Cancer Coalition, Trebek participated in a worldwide awareness initiative wherein he encouraged the public to know the risk factors and the symptoms of the deadly disease. His fame sparked conversation about pancreatic cancer while showing the patients across the world that cancer does not define a person. While Trebek made great efforts to bring awareness to pancreatic cancer, some celebrities choose not to use their diagnosis to spearhead conversation. Actor Chadwick Boseman battled colon cancer before passing away in mid-2020. Unlike Trebek, he chose to keep his journey private. After his death, however, a wave of colon cancer awareness flooded the world. Both Trebek and Boseman are beloved by their fans; however the differences between their journeys with cancer highlight that, even as a celebrity, a cancer diagnosis is an extremely personal experience. For Trebek, raising awareness and talking about his difficult prognosis helped him cope with the news. Boseman found strength in continuing his life as normal, only discussing his cancer treatment with those closest to him. Trebek and Boseman are perfect and timely examples of how each person copes differently. There is no correct way to deal with a cancer diagnosis – whether a new diagnosis or an ongoing experience. Like many aspects of life, seeing someone else handle a situation differently can cause doubt with one’s own approach. However, as Trebek and Boseman nobly demonstrated, deciding whether to speak about a cancer diagnosis publicly is a personal choice. There is no right or wrong way for any patient to navigate such a decision. Each journey […]

New Study Suggests Strong Social Support Can Improve Cancer Outcomes

Study conducted by researchers at Kaiser Permanente found women diagnosed with colorectal cancer who had low social support before diagnosis were more likely to succumb to their illness. A new study from researchers at Kaiser Permanente sheds light on the importance of social support for women diagnosed with colorectal cancer. Because March is colorectal cancer awareness month, understanding the critical role of social support for women diagnosed with the disease can help health care providers, caregivers, and communities take steps to ensure that women affected by the illness receive the proper support at the time they need it most.  Breaking Down the Study Findings Led by Candyce Kroenke, MPH, ScD, a research scientist with the Kaiser Permanente Division of Research, the study analyzed data from 1,429 women enrolled in the Women’s Health Initiative, a long-term national study focused on strategies to prevent heart disease, breast and colorectal cancer, and osteoporosis in post-menopausal women.  Kroenke and her team focused on the women’s social support systems — including personal connections, links with their communities, and living status (single, cohabitating, or married) — and discovered that women diagnosed with colorectal cancer who reported low social support prior to their diagnosis experienced 42 percent higher mortality than those who reported high levels of support. Their findings build on previous research conducted by Kroenke in 2016, which tied strong social support to improved outcomes for breast cancer patients, and further confirm the importance of such support for patients diagnosed with serious illnesses.  Published in the journal Cancer on Jan. 23, the study encourages patients who have been diagnosed with a serious illness such as colorectal cancer to turn to others for support when needed. It also recommends that health care providers work to identify those patients who could benefit from additional social support and connect them with resources that might be able to assist them. Read the full article here. Identifying Social Support for Colorectal Cancer Patients For patients who lack social support from their families and communities, the National Cancer Institute provides a wealth of resources to help connect them with other support services, including cancer support groups. Cancer support groups host meetings that patients diagnosed with cancer and their caregivers can attend, often at no cost. According to the National Cancer Institute, cancer support groups for patients diagnosed with colorectal cancer and other serious illnesses can: Help patients feel more hopeful about their diagnosis Give patients and opportunity to talk and work through their feelings Help patients cope with practical issues, such as problems at work or school Help patients deal with side effects associated with their treatments In addition, some support groups are offered online or over the telephone to ensure that patients who are not able to travel to attend meetings in person are still able to receive important social support. Visit the National Cancer Institute website for more information. Working Towards a Cancer-Free World In a perfect world, there would be no need for cancer support groups for colorectal cancer patients, because the disease could be cured just as quickly as it is detected. While we aren’t there yet, National […]

Colorectal Cancer: A Serious, But Preventable Disease

March is colorectal cancer awareness month. Learn the signs and symptoms, as well as steps that you can take to help reduce your risk. March is colorectal cancer awareness month. Although colorectal cancer can be a devastating disease, it is also very preventable thanks to the development of advanced screening tools. Knowing the signs and symptoms of this illness, as well as taking advantage of preventative screening measures can help you significantly reduce your risk and live a longer, healthier life. Colorectal cancer is the term used to describe any cancer that begins in the colon or rectum. The colon and rectum are both part of the large intestine, and play an integral role in the body’s digestive system.  Colorectal cancer often begins as a growth in the lining of the colon or rectum, known as a polyp. Not all polyps are cancerous, but certain types can turn into cancer if left untreated. Individuals diagnosed with colorectal cancer often experience the following symptoms: Bloating Blood in stool Diarrhea or constipation Feeling as though the bowel does not completely empty Gas pains or cramps Narrow stools Nausea or vomiting Unintended weight loss Because symptoms usually do not appear until the disease is advanced, people with certain risk factors should work with their health care provider to make sure they receive the proper preventive screenings. Risk factors that can increase a person’s chance of developing colorectal cancer include: Age: Individuals age 50 years and older are at an increased risk for developing colorectal cancer. Race/Ethnicity: African Americans are at an increased risk for developing this disease compared to people of other races/ethnicities. Family Medical History: Individuals with a family history of colorectal cancer, ulcerative colitis, or Crohn’s disease have a higher chance of developing the disease. Lifestyle Choices: Individuals who eat a diet high in fat or smoke have a greater risk of developing colorectal cancer than those who do not. Proactive screening measures can help reduce an individual’s risk for developing colorectal cancer, including colonoscopy and tests to identify whether blood is present in the stool. The Latest Research in the Field Cutting-edge research in laboratories across the United States and around the world aims to help ensure that individuals diagnosed with colorectal cancer live longer, healthier lives. In fact, recent advances in treatment have already started saving lives. Major League Baseball player Darryl Strawberry, talk show host Sharon Osbourne, and U.S. Supreme Court Justice Ruth Bader Ginsburg have all been diagnosed with and successfully treated for colorectal cancer in recent years. Research focuses on helping investigators learn more about the disease, develop new methods to prevent and treat the illness, and establish best practices for caring for individuals diagnosed with the condition. Current studies aim to develop improved detection methods for colorectal cancer, new tests to predict the risk of cancer recurrence, new immunotherapies that target special checkpoint inhibitors, targeted therapies aimed at genetically mutated colorectal tumors, new chemotherapies and other targeted therapies, and improved palliative care practices. At the National Foundation for Cancer Research (NFCR), fellow Wei Zhang, PhD, director of cancer genomics and precision oncology at the Comprehensive […]